An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy

Since multiple novel treatments for immunoglobulin A nephropathy (IgAN) have become available in recent years, with many more in development, the 2021 Kidney Disease: Improving Global Outcomes clinical practice guidelines are of limited relevance in modern practice These novel agents specifically target the underlying disease pathophysiology of IgAN for improved efficacy and safety, but their place in the IgAN treatment approach has not been establishedTo address the need for updated guidance, this article proposes a novel approach to IgAN treatment based on the author's clinical expertise and interpretation of the available literature, which incorporates the established, recently approved, and latephase-development pipeline agents Although this approach may serve as a general guide for clinicians, it is most important to consider the clinical and pathologic characteristics of individual patients when making treatment decisions in IgAN